Literature DB >> 4030539

Vancomycin toxicity: a prospective study.

J A Mellor, J Kingdom, M Cafferkey, C T Keane.   

Abstract

A prospective study of 34 patients treated with 39 courses of intravenous vancomycin, was undertaken in order to assess toxicity. Six patients received vancomycin alone and 27 courses were associated with aminoglycoside administration either concurrently or within two weeks of the first dose of vancomycin. Hearing loss was slight and uncommon; patients were unaware of its occurrence. Tinnitus and dizziness was noted by two patients and resolved on withdrawal of vancomycin. Diminution of renal function was seen both during (7%) and after (9%) vancomycin therapy. A striking feature of these patients with renal deterioration was the severity of their underlying disease. No evidence of synergistic toxicity between vancomycin and aminoglycosides was seen.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4030539     DOI: 10.1093/jac/15.6.773

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  22 in total

Review 1.  Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.

Authors:  Sepideh Elyasi; Hossein Khalili; Simin Dashti-Khavidaki; Amirhooshang Mohammadpour
Journal:  Eur J Clin Pharmacol       Date:  2012-03-13       Impact factor: 2.953

Review 2.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

3.  Intrarenal distribution of vancomycin in endotoxemic rats.

Authors:  M Ngeleka; P Auclair; D Tardif; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.

Authors:  Michael M Kheir; Timothy L Tan; Ibrahim Azboy; Dean D Tan; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2017-07       Impact factor: 4.176

5.  Cost-ineffectiveness of serum vancomycin levels.

Authors:  B A Cunha; S S Mohan; N Hamid; B P McDermott; P Daniels
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

6.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

7.  BPEI-Induced Delocalization of PBP4 Potentiates β-Lactams against MRSA.

Authors:  Melissa A Hill; Anh K Lam; Patricia Reed; Madeline C Harney; Beatrice A Wilson; Erika L Moen; Summer N Wright; Mariana G Pinho; Charles V Rice
Journal:  Biochemistry       Date:  2019-08-26       Impact factor: 3.162

Review 8.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.

Authors:  T Lawrence; C Rotstein; T R Beam; E A Gorzynski; D Amsterdam
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 10.  Glycopeptides and nephrotoxicity.

Authors:  A W Chow; R M Azar
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.